Chemotherapy and radiotherapy in the management of gastric cancer

Current Opinion in Gastroenterology

Volumn 21, Issue 6, 2005, Pages 673-678

  Leong, Trevor ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Adjuvant therapy; Chemotherapy; Gastric cancer; Radiotherapy

Indexed keywords

ANGIOGENESIS INHIBITOR; CAPECITABINE; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONIST; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHOTREXATE; OXALIPLATIN; PROTEIN TYROSINE KINASE INHIBITOR; RADIOSENSITIZING AGENT; RECEPTOR BLOCKING AGENT; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

AGRANULOCYTOSIS; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG TOLERABILITY; GASTRECTOMY; GASTROINTESTINAL SYMPTOM; HUMAN; INTERMETHOD COMPARISON; METASTASIS; NEUTROPENIA; PATIENT CARE; PERIPHERAL NEUROPATHY; REVIEW; STOMACH CANCER; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HUMANS; NEOADJUVANT THERAPY; RADIOTHERAPY, ADJUVANT; STOMACH NEOPLASMS;

EID: 27744446188     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mog.0000179833.28158.b7     Document Type: Review

References (42)

1. Neugut AI, Hayek M, Howe G. Epidemiology of gastric cancer. Semin Oncol 1996; 23:281-291.
2. Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049-2053.
3. Glimelius B, Ekstrom K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8:163-168.
4. Pyrhonen S, Kuitunen T, Nyandoto P, et al. Randomised comparison of fluo-rouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71:587-591.
5. Murad AM, Santiago FF, Petroianu A, et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993; 72:37-41.
6. Ychou M, Astre C, Rouanet P, et al. A phase II study of 5-fluorouracil, leucovorin and cisplatin (FLP) for metastatic gastric cancer. Eur J Cancer 1996; 32A:1933-1937.
7. Janunger KG, Hafstrom L, Nygren P, et al. A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol 2001; 40:309-326.
8. Waters JS, Norman A, Cunningham D, et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 1999; 80:269-272.
9. Ilson DH. Epirubicin, cisplatin, and fluorouracil in gastric and esophageal cancer: a step ahead? J Clin Oncol 2002; 20:1962-1964.
10. Ajani JA. Standard chemotherapy for gastric carcinoma: is it a myth? J Clin Oncol 2000; 18:4001-4003.
11. Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002; 20:1996-2004.
12. Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18: 2648-2657.
13. Woynarowski JM, Faivre S, Herzig MC, et al. Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol 2000; 58:920-927.
14. Kollmannsberger C, Rick O, Derigs HG, et al. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 2002; 20: 2031-2037.
15. Extra JM, Espie M, Calvo F, et al. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990; 25:299-303.
16. Kim DY, Kim JH, Lee SH, et al. Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer. Ann Oncol 2003; 14:383-387.
17. Louvet C, Andre T, Tigaud JM, et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 2002; 20:4543-4548.
18. Al-Batran SE, Atmaca A, Hegewisch-Becker S, et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 2004; 22:658-663. Biweekly infusion of 5-fluorouracil, leucovorin, and oxaliplatin (with reduced doses of 5-fluorouracil and oxaliplatin compared with FOLFOX6) achieved, in patients with advanced gastric cancer, an overall response rate of 43% and median survival of 9.6 months with very little toxicity.
19. Chao Y, Yeh KH, Chang CJ, et al. Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer. Br J Cancer 2004; 91:453-458.
20. Sumpter KA, Harper-Wynne C, Cunningham D, et al. Randomised, multicenter phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer: confirmation of dose escalation. Proc Am Soc Clin Oncol 2003; 22: 257.
21. Ajani JA, Baker J, Pisters PW, et al. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer 2002; 94:641-646.
22. Boku N, Ohtsu A, Shimada Y, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999; 17: 319-323.
23. Blanke CD, Haller DG, Benson AB, et al. A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma. Ann Oncol 2001; 12:1575-1580.
24. Assersohn L, Brown G, Cunningham D, et al. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol 2004; 15: 64-69.
25. Bouche O, Raoul JL, Bonnetain F, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologic Digestive Group Study-FFCD 9803. J Clin Oncol 2004; 22: 4319-4328. Biweekly administration of 5-fluorouracil and leucovorin in combination with irinotecan achieved a 40% response rate and median survival of 11.3 months in patients with metastatic gastric cancer.
26. Ajani JA, Van Cutsem E, Moiseyenko V, et al. Docetaxel (D), cisplatin, 5-fluorouracil compare to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naive patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): Interim results of a randomized phase III trial (V325). Proc Am Soc Clin Oncol 2003; 22:249.
27. Roth AD, Maibach S, Falk S, et al. Docetaxel-cisplatin-5FU (TCF) versus docetaxel-cisplatin (TC) versus epirubicin-cisplatin-5FU (ECF) as systemic treatment for advanced gastric carcinoma (AGC): a randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). Proc Am Soc Clin Oncol 2004; 23:317. Preliminary results of a randomized trial demonstrating the efficacy of a new docetaxel-based chemotherapy regimen (TCF) for patients with advanced gastric cancer.
28. Thuss-Patience PC, Kretzschmar A, Repp M, et al. Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. J Clin Oncol 2005; 23: 494-501. Docetaxel plus 5-fluorouracil achieved an overall response rate of 37.8% and median survival of 9.5 months. The results compare favorably with ECF with the advantage that docetaxel/5-fluorouracil is more easily administered in an outpatient setting.
29. Hermans J, Bonenkamp JJ, Boon MC, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993; 11:1441-1447.
30. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 1999; 35:1059-1064.
31. Mari E, Floriani I, Tinazzi A, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol 2000; 11:837-843.
32. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345:725-730.
33. Leong T, Michael M, Foo K, et al. Adjuvant and neoadjuvant therapy for gastric cancer using epirubicin/cisplatin/5-fluorouracil (ECF) and alternative regimens before and after chemoradiation. Br J Cancer 2003; 89:1433-1438.
34. Fuchs C, Fitzgerald T, Mamon H, et al. Postoperative adjuvant chemoradiation for gastric or gastroesophageal adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (RT): a multicenter pilot study. Proc Am Soc Clin Oncol 2003; 22:257.
35. Komaki R, Janjan NA, Ajani JA, et al. Phase I study of irinotecan and concurrent radiation therapy for upper GI tumors. Oncology 2000; 14:34-37.
36. Safran H, Wanebo HJ, Hesketh PJ, et al. Paclitaxel and concurrent radiation for gastric cancer. Int J Radiat Oncol Biol Phys 2000; 46:889-894.
37. Leong T, Willis D, Joon DL, et al. 3D Conformal radiotherapy for gastric cancer-results of a comparative planning study. Radiother Oncol 2005; 74:301-306. This study demonstrates how the use of modern conformal radiotherapy techniques for treating gastric cancer can reduce treatment-related toxicity.
38. Wieland P, Dobler B, Mai S, et al. IMRT for postoperative treatment of gastric cancer: covering large target volumes in the upper abdomen: a comparison of a step-and-shoot and an arc therapy approach. Int J Radiat Oncol Biol Phys 2004; 59:1236-1244.
39. Allum W, Cunningham D, Weeden S. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: a randomised, controlled trial (the MRC MAGIC trial, ISRCTN 93793971). Proc Am Soc Clin Oncol 2003; 22: 249.
40. Zhang ZX, Gu XZ, Yin WB, et al. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC): report on 370 patients. Int J Radiat Oncol Biol Phys 1998; 42:929-934.
41. Ajani JA, Mansfield PF, Janjan N, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 2004; 22:2774-2780. This study demonstrates that a new strategy employing preoperative chemoradiation is associated with a high pathological complete response rate.
42. Ajani JA, Mansfield PF, Crane CH, et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 2005; 23: 1237-1244.